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Abstract
Chronic inflammation has long been associated with a wide range of malignancies, is now widely
accepted as a risk factor for development of cancer, and has been implicated as a promoter of a
variety of cancers including hematopoietic malignancies. We have described a mouse model
uniquely suited to examine the link between inflammation and lymphoma in which the Tax
oncogene, expressed in activated T and NK cells, perpetuates chronic inflammation that begins as
microscopic intraepithelial lesions and develops into inflammatory nodules, subcutaneous tumors,
and large granular lymphocytic leukemia. The use of bioluminescent imaging in these mice has
expanded our ability to interrogate aspects of inflammation and tumorigenesis non-invasively. Here
we demonstrate that bioluminescence induction in these mice correlated with inflammation
resulting from wounding, T cell activation, and exposure to chemical agents. In experiments in
which long-term effects of inflammation on disease outcome were monitored, the development of
lymphoma was promoted by an inflammatory stimulus. Finally we demonstrated that activation of
T-cells in T-cell receptor (TCR) transgenic TAX-LUC animals dramatically exacerbated the
development of subcutaneous TCR- CD16+ LGL tumors. The role of activated T-cells and acquired
immunity in inflammation-associated cancers is broadly applicable to hematopoietic malignancies,
and we propose these mice will be of use in dissecting mechanisms by which activated T-cells
promote lymphomagenesis in vivo.
Background
Malignant transformation of the cancer cell is promoted
and often preceded by changes in the tumor microenvi-
ronment, rich in inflammatory cells, growth factors, and
DNA damage promoting agents. A wide range of malig-
nancies are promoted by chronic inflammation associated
with chemical, physical, or microbial factors [1-4]. The
diversity of oncogenic factors associated with inflamma-
tion highlights the importance of characterizing those
common to a wide range of malignancies. The cellular
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effectors, signaling pathways, and secreted regulators
involved in chronic inflammation are the soil in which
the seeds of these cancers are initiated.
T-cells are central regulators of the immune response; T-
cells are recruited to sites of chronic inflammation, and
the infiltration of T-cells within the tumor is a critical
determinant of neoplastic outcome. Naïve CD4+ T-cells,
or T-helper cells, that have not previously encountered an
antigen differentiate into one of four committed lineages
(TH1, TH2, TH17, Treg) in response to antigen presenting
cells [5-10]. Conventionally, TH1 and TH2 cells promote
the elimination of intracellular and extracellular patho-
gens respectively. More recently TH17 cells have been
characterized for their ability to promote inflammation by
recruiting neutrophils to peripheral tissues to remove
extracellular pathogens, while Treg cells repress inflamma-
tion to keep immune hyperactivity in check. While there
is no question that T-cells are recruited to sites of chronic
inflammation, it is unclear whether activated T-cells pro-
mote or restrict malignancies in vivo.
Molecular pathways often involved in inflammation-
associated tumorigenesis include JNK, STAT3, HIF-1, and
nuclear factor κB (NFκB) signaling, and generation of
reactive oxygen species [1,3,11,12]. These pathways are
interrelated and signaling through NFκB serves as a master
regulator. NFκB signaling during tumorigenesis prevents
apoptosis and promotes proliferation, metastasis, and
angiogenesis [13]. NFκB is activated in T-lymphocytes
after T-cell receptor (TCR) engagement, as well as in other
cell types through activation of toll-like receptors (TLR)
[11,14,15]. NFkB is over-expressed in a wide range of
malignancies, particularly cancers refractory to chemo-
therapy [16,17].
Soluble mediators of migration, proliferation, and signal-
ing pathways of cells in the tumor microenvironment
include cytokines and chemokines. The balance of
cytokines produced in a tumor regulates the type and
extent of inflammatory infiltrate, the level of cytotoxicity
and genetic instability, the degree of neovascularization,
and the innate and adaptive immune responses to the
tumor [14,16,17].
We have developed and characterized a triple transgenic
mouse model of inflammation-associated cancer that
allows us to experimentally activate T cells and NFkB sig-
naling pathways prior to the onset of tumorigenesis and
to non-invasively monitor inflammation and tumor pro-
gression using bioluminescent imaging (BLI). The first
transgene expresses the human T-cell leukemia virus type
1 (HTLV-1) Tax oncogene under the granzyme B promoter
(GZB), which restricts expression to activated T- and NK-
cells [18,19]. In activated T- and NK- cells of these mice,
Tax constitutively activates both the canonical and non-
canonical pathways of NFkB [20]. Moreover, tumors that
arise in GZB-TAX mice are composed of malignant
CD16hi large granular lymphocytes (LGLs), infiltrating
CD16lo neutrophils, and CD16- T- and B- lymphocytes
[18,20-25]. Moreover, Tax stimulates and recruits inflam-
matory cells through induction of IFN-gamma, IL-1, IL-6,
GM-CSF, RANK ligand, and TNFα [21,24,26].
The second transgene expresses firefly luciferase (LUC)
under the regulation of the HTLV-1 LTR. When mice carry
both the LTR-LUC and GZB TAX transgenes (TAX-LUC
mice), the events associated with the expression of Tax,
including T-cell activation, constitutive NFKB activation,
and spontaneous tumorigenesis, can be monitored non-
invasively by BLI. In these mice, inflammation was closely
correlated with lymphomagenesis, and sensitive imaging
technology enabled us, for the first time, to identify all
stages in spontaneous tumor development including pri-
mary microscopic lesions, pre-malignant inflammatory
nodules, localized tumors, and disseminated disease [25].
Thus in TAX-LUC mice, Tax expressed in mature lym-
phocytes activates luciferase expression which is detected
non-invasively using D-luciferin as a substrate for BLI.
Moreover, we recently described the use of luminol to
monitor neutrophil myeloperoxidase activity, using the
same imaging modality, as an independent reporter for
tumor associated inflammation [27].
The third transgene is a genetic manipulation of the T-cell
receptor that restricts its recognition to ovalbumin such
that activation of T- cells in TCR transgenic mice can be
experimentally induced by administration of ovalbumin.
The majority of circulating T- cells are activated in TCR-
OVA transgenic animals upon administration of ovalbu-
min [6,7]. The combination of these three transgenes and
the properties of the oncoprotein Tax, gave us the ability
to activate T cells, stimulate NFkB pathways, promote
inflammation, and image these processes non-invasively
using luciferase mediated BLI. We used this model to
determine whether activated T- cells promote or suppress
tumorigenesis in vivo. We discovered that the activation of
T- cells in triple transgenic mice dramatically exacerbated
tumor development and the onset and dissemination of
LGL lymphoma. We propose that these findings are appli-
cable to many forms of hematologic malignancy espe-
cially those associated with constitutive activation of
NFkB and chronic inflammation. We further propose that
this animal model will be a broadly useful tool in the




Individual strains of transgenic mice utilized in this report
have been previously described. In LTR-LUC, the 0.7 Kb
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ferase (pGL-3; Promega) [25]. In GZB-TAX, HTLV-1 Tax is
regulated by the 5' flanking region (-1170 to +36) of the
human granzyme B gene [18]. Mice were housed under
pathogen free conditions and animal protocols were
approved by the Animal Studies Committee in accordance
with the guidelines of the Washington University School
of Medicine.
Flow Cytometry
Cell suspensions derived from organs or tumors were
stained with FITC-conjugated FcγR II/III antibodies (clone
2.4G2; BD Pharmingen) for 30 minutes at 4°C and ana-
lyzed on a FACScan (Becton Dickinson). In three color
experiments, cells were incubated with unlabelled FcγR II/
III antibodies for 30 minutes to block free surface FcγR,
and counterstained with PE-conjugated antibodies
against TCRova (clone KJ1-26; eBioscience) and PE-Cy5
conjugated anti-CD4 (cloneGK1.5 eBioscience).
Imaging
The IVIS100 system (Xenogen) was used to image biolu-
minescence in anesthetized mice (isoflurane inhalation).
Standard imaging parameters included D-luciferin dose
15 mg i.p; luminol dose 200 mg/kg i.v; exposure 300 sec;
binning 4; f/stop 1; no optical filter. When luminol and
D-luciferin images were obtained from the same animal,
the first substrate was allowed to clear for 24 hours prior
to injection with the second. When necessary, hair was
removed by shaving or depiliation prior to imaging. Color
scale unless otherwise indicated is ×104 photons/sec/cm2/
sr. The indicated agents were injected ip at the following
dosages: con A, 2.5 mg/kg; LPS, 2.5 mg/kg; CFA, 100 μl in
100 μl PBS; poly(I:C), 1 mg/kg. For experiments involving
BrdU, animals were injected with 1 mg BrdU, i.p. (BD
Pharmingen) 24 hours prior to necropsy.
Histology
Histology was performed as described [25]. Briefly, tissues
were fixed in 4% paraformaldehyde and embedded in
paraffin for serial sectioning. The primary BrdU antibody
(Dako clone Bu20a) was used at a dilution of 1:150. The
biotinylated primary antibody was incubated for 1 hour
and labeled streptavidin applied for 30 minutes. Slides
were developed with DAB chromogen then counter-
stained in Richard Allen hematoxylin. Sections were visu-
alized with a Nikon Eclipse E400 microscope and digital
images were obtained using a Magnafire camera and soft-
ware (Optronics).
Results
Imaging Inflammation and Tumorigenesis in vivo
TAX-LUC mice are doubly transgenic mice in which i) the
Tax gene from HTLV-1 is restricted to activated NK and T
cells by the granzyme B promoter and ii) luciferase, under
the control of the HTLV-1 LTR, is activated by Tax [25]. In
principle, luciferase, which catalyzes a light emitting reac-
tion in the presence of its substrate D-luciferin, serves as
an indirect biomarker for activated NK and T cells in TAX-
LUC mice. Alternatively, upon activation of leukocytes
during inflammation, neutrophil myeloperoxidases are
expressed that catalyze the production of hypochlorous
acid from hydrogen peroxide and chloride ions [27].
Luminol emits light when exposed to oxidizing agents
and can be used to sensitively and non-invasively detect
leukocyte activity during inflammation in vivo. We have
shown that administration of either luminol or D-luci-
ferin produces bioluminescence in primary TAX-LUC
tumors and that microscopic bioluminescent lesions pre-
cede tumorigenesis. We sought to determine the effects of
inflammation on bioluminescence and tumorigenesis in
this model.
We first asked whether wounding was sufficient to result
in a luciferase-mediated bioluminescent signature in TAX-
LUC mice. We found that minor incisions on the ear, tail
or foot (Fig. 1) were sufficient to produce a significant bio-
luminescent signature and that introduction of adjuvant
in the wound increased the intensity and duration of the
signal. These data confirmed a close correlation between
wounding and reporter expression in vivo.
Generalized T Cell Activation is Associated with 
Tumorigenesis
While Tax is activated in malignant LGL cells of inflamed
tumors, the granzyme B promoter is also inducible in T
and NK cells by T-cell receptor (TCR)-dependent, TCR-
independent, and cytokine-mediated stimuli [28]. A
number of direct and indirect inducers of generalized T
cell activation were utilized to locally activate this pro-
moter and image Tax activity during inflammation. These
included phorbol 12-myristyl 13-acetate (PMA), which
when administered topically, promotes T lymphocyte
infiltration and activation mediated by protein kinase C,
and has been shown to stimulate the human granzyme B
promoter in transgenic mice [29,30]. Topical administra-
tion of PMA to the ear resulted in luciferase based biolu-
minescence in TAX-LUC mice, but not LTR-LUC mice (Fig.
2A, top panels) even though a massive inflammatory infil-
trate was seen in all PMA treated ears (Fig. 2B). Luminol
based bioluminescence emanating from the PMA treated
ears compared to the vehicle treated contralateral ears
(Fig. 2A, bottom panels) served as a reporter for inflam-
mation. The intensity of luminol BLI after PMA treatment
was greater in TAX-LUC mice than LTR-LUC littermates
that lack the Tax transgene (fold flux increase 11.5 vs. 7.4;
p = 0.018). These findings serve as proof of principle for
the appropriate regulation of the transgenes in TAX-LUC
mice, confirm that acute inflammation is sufficient to pro-
duce bioluminescence in this model, and suggest that Tax
expression exacerbates the inflammatory response in vivo.Retrovirology 2009, 6:116 http://www.retrovirology.com/content/6/1/116
Page 4 of 10
(page number not for citation purposes)
Wound induced bioluminescence in TAX-LUC mice Figure 1
Wound induced bioluminescence in TAX-LUC mice. 
Surgical lesions were experimentally introduced in ear (A) 
limb (B), and tail tissue (C). The effect of adjuvant on wound 
associated bioluminescence was also examined (B, C). Treat-
ments include 1) vehicle, 2) CFA, 3) wound, and 4) wound 
and CFA. Images were obtained 0.5 hrs before treatment, 
and 0.5, 2, 24, and 48 hrs after treatment. Representative 
images shown from A) 30 minutes, B) 2 hours, and C) 24 and 
48 hours after treatment.
Phorbol myristyl acetate stimulation of bioluminescence in  transgenic mice Figure 2
Phorbol myristyl acetate stimulation of biolumines-
cence in transgenic mice. For each mouse, the left ear 
was treated with PMA and the right ear with vehicle. A) Rep-
resentative images obtained 2 hours after treatment are 
shown for two LTR-LUC mice (left panels) and two TAX-
LUC mice (right panels) comparing bioluminescence follow-
ing administration of D-luciferin (top panels) and Luminol 
(bottom panel). B) Histology showing edema and inflamma-
tory infiltrate associated with topical application of PMA (48 
hours; Bar = 1 mm). C) Aggressive lymphoma in TAX-LUC 
mice from intravenous administration of con A. D) Histology 
is H/E stained sections of bioluminescent tumors in the cervi-
cal lymph nodes and small intestine of a con A treated TAX-
LUC mouse.Retrovirology 2009, 6:116 http://www.retrovirology.com/content/6/1/116
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Con A, a potent lectin with broad activity towards T lym-
phocytes, is also known to activate the granzyme B pro-
moter. To determine whether induction of inflammation
affected tumorigenesis in this model, we examined 5 TAX-
LUC mice and 5 LTR-LUC in each group given tail vein
injections of con A or saline (Fig. 2C). While TAX-LUC
mice develop peripheral tumors most frequently on the
tail, this method of con A inoculation is known to prefer-
entially target T cell activation in the liver [31,32]. All 5
con A treated mice developed liver bioluminescence, and
two died within 1 week of acute hepatitis. The other 3 con
A treated mice developed lymphoma initiated in the liver
with spread to the gastrointestinal tract, spleen, and cervi-
cal nodes, as detected by BLI and histological analysis at
necropsy (Fig. 2C). While the 5 saline injected TAX-LUC
mice developed tail tumors, none developed a similar
form of aggressive lymphoma, characterized by massive
visceral infiltration. LTR-LUC animals did not develop
tumors. This experiment suggested that con A-induced
inflammation and T cell activation in TAX-LUC mice were
sufficient to modify the presentation of lymphoma from
peripheral and indolent to visceral and aggressive.
We also utilized CFA a mixture of paraffin oil, surfactant,
and heat-killed mycobacteria that leads to TH1 lym-
phocyte activation [33]. In addition, we examined induc-
ers of T cell activation through effects on TLRs on antigen-
presenting cells (APCs). These inducers included poly I:C,
a mimic of double stranded RNA that activates the inter-
feron response, and LPS, found in the cell wall of gram
negative bacteria, that rapidly activates pyrogenic
cytokines and cells involved in innate immunity [34]. In
the tumors that arise in TAX-LUC animals, the malignant
cells are rarely T cells, but instead are CD16Hi LGLs that
lack TCRs. Primary TAX-LUC tumors also contain a large
population of CD16Lo cells which are predominantly neu-
trophils and CD16- cells which include tumor infiltrating
T cells. We next sought to determine if bioluminescence
resulting from acute inflammation correlates with the
recruitment or proliferation of CD16Hi LGLs. The repre-
sentative results of intraperitoneal injections into 3 mice
each of saline, con A, CFA, poly I:C, and LPS are shown in
Fig. 3. Mice were imaged 0.5 hour prior to injections and
then at 2 and 6 hours after injection, then sacrificed and
examined. BLI performed prior to injection exhibited very
low background levels of activity primarily within the gas-
trointestinal tract TAX-LUC mice. Con A treatment
resulted in increased numbers of CD16lo cells and BrdU+
cells in the spleen and liver compared to saline treated
animals (Fig. 3A, B), whereas the number of CD16Hi cells
increased in spleen but not liver. After con A injection BLI
was increased in the gastrointestinal tract and liver as
compared to saline injected animals (Fig. 3C). Intraperi-
toneal injection of CFA was similar to the effects of con A.
The number of BrdU positive cells in the spleen and liver
was increased after CFA treatment, and infiltrates of lym-
phoid cells in the liver were apparent. Two hours after
CFA injection, bioluminescence localized primarily to the
liver (Fig. 3C). Intraperitoneal injection of poly(I:C) and
LPS also resulted in increased numbers of CD16lo cells
and BrdU+ cells in spleen and liver compared to animals
injected with saline. Unlike Con A and CFA, biolumines-
cence in TAX-LUC mice after treatment with poly(I:C) and
LPS was more evident in the spleen and gastrointestinal
tract than liver.
Taken together, these studies indicated that biolumines-
cence in TAX-LUC mice serves as a sensitive indicator of
acute inflammation in vivo. However, the biolumines-
cence profile does not correlate with CD16Hi cells nor pro-
liferating cells, suggesting the light emitting cells during
inflammation are not identical to the population of cells
that subsequently undergo malignant transformation.
While malignant LGLs in TAX-LUC tumors are biolumi-
nescent, these results demonstrated that during acute
inflammation other luciferase-expressing cell types pre-
dominate, possibly activated T cells. Based on these find-
ings, we sought to use a genetic approach to determine if
activated T cells promote tumorigenesis in TAX-LUC mice.
Specific T-Cell Receptor Activation Accelerates Tax-
Mediated Tumorigenesis
DO11.10 mice carry a transgenic MHC class II restricted
rearranged T cell receptor which reacts with a specific oval-
bumin (OA) peptide antigen [6,7]. IP administration of
OA results in deletion of immature CD4+ CD8+ TCRlo thy-
mocytes and expansion of CD4+  TCRHi  thymocytes.
Within 3 days post injection all of the immature non-OVA
reactive thymocytes are removed and OA reactive CD4+ T
cells represent approximately 70% of T cells in these mice.
In order to examine the specific effects of TCR activation,
triple transgenic mice were utilized, resulting from breed-
ing TAX-LUC mice with DO mice (Fig. 4). In one experi-
ment, 5 TAX-LUC-DO mice were inoculated with OA in
CFA, and 2 control TAX-LUC-DO mice were inoculated
with CFA alone. Double transgenic LUC-DO and TAX-
LUC mice were also inoculated with OA in CFA to serve as
controls. The immune response to OA in CFA could be
observed non-invasively in these mice using BLI (Fig. 4A-
B) which served as an internal control to ensure each
immunization produced a response. Bioluminescence
was detectable 7 hours after injection and by day 3 pre-
dominantly localized to the spleen (Fig. 4A). Subsequent
injections in primed animals produced a bioluminescent
response of increased intensity and duration (Fig. 4B).
Interestingly, bioluminescence was also detected in LUC-
DO animals, although it was more intense in Tax trans-
genic animals (Fig. 4C). These results demonstrate that
OA in CFA is sufficient to activate basal HTLV LTR tran-
scriptional activity, which is further activated by inductionRetrovirology 2009, 6:116 http://www.retrovirology.com/content/6/1/116
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of Tax expression in TAX-LUC-DO mice. Over the course
of 1 year, 4-10 tail tumors arose in each of the TAX-LUC-
DO mice inoculated with OA in CFA, and 2-3 tail tumors
arose in each of the TAX-LUC mice (Fig. 4C, numbers at
bottom of panels). No tumors arose in mice lacking the
Tax transgene (LUC-DO), nor in the two TAX-LUC-DO
controls that received no OA.
These findings were confirmed and extended in addi-
tional experiments (Fig. 5A). Significantly more tumors
were noted in triple transgenic TAX-LUC-DO mice inocu-
lated with OA in CFA compared to those inoculated with
CFA alone (6.5 vs 3.1, p = 0.0014) (Fig. 5A, panel 1).
Moreover, survival was significantly shorter in TAX-LUC-
DO and TAX-DO mice treated with OA in CFA compared
to those administered CFA alone (Fig. 5B). No tumors
developed in the absence of the Tax transgene in LUC-DO
mice, DO mice, or LUC mice (Fig. 5A, panels 2, 3, and 4,
respectively). Doubly transgenic TAX-LUC mice lacking
the specific TCR had fewer tumors in the presence than
absence of OA (1.5 vs. 4.3 p = 0.0083). Since the average
tumor onset in Tax mice occurs within 200-300 days and
Bioluminescence in TAX-LUC mice correlates with inflammatory response Figure 3
Bioluminescence in TAX-LUC mice correlates with inflammatory response. Representative data are shown from 
groups of 3 mice each inoculated intraperitoneally with saline, con A, CFA, poly (I:C), or LPS. A) FACS histograms for CD16lo 
cells (red curve) and CD16hi cells (black curve) in liver and spleen 6 hrs after treatment. B) Representative BrdU IHC results 
from the spleen and liver. C) Bioluminescent images obtained 2 hrs after treatment. Bar = 1 mm.Retrovirology 2009, 6:116 http://www.retrovirology.com/content/6/1/116
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many animals do not develop tumors until the second
year of life, some Tax positive animals did not develop
tumors during the time course of this experiment [18].
While the OA-restricted TCR in TAX-LUC-DO animals is
expressed on CD4+ lymphocytes, the presence of TCRova
cells in tumors was variable. Typically, the malignant LGL
population in tumors that spontaneously arise in TAX-
LUC mice is TCR-, and tumor infiltrating lymphocytes are
TCR+. This is consistent with what we observed in tumors
arising on the tails in TAX-LUC-DO mice which included
both TCR- and TCR+ cells (Fig. 5C). In contrast, tumors
arising in the gastrointestinal (GI) tract, which were only
found in TAX-LUC-DO animals treated with OA, were
composed of TCR+ cells with a minor population of cells
expressing exceptionally high levels of TCRova (Fig. 5C).
Alternatively, tumors arising in the ears contained very
few TCR+ cells and were primarily composed of malignant
LGLs. Representative histology (Fig. 5D) for tumors aris-
ing in OA stimulated TAX-LUC-DO mice, includes exam-
ples of tumors invading spleen, lung, and liver as well as
primary tumors arising in intestine and peripheral tissues.
In each case, a proliferation of lymphoid cells is evident,
however, the size, morphology, and expression profiles of
CD16 and TCRova indicated that tumors arising in the gut
were distinct from peripheral tumors that typically arise
Bioluminescence imaging of T-cell receptor activation in TAX-LUC-DO mice Figure 4
Bioluminescence imaging of T-cell receptor activation in TAX-LUC-DO mice. Image (A) and quantitation (B) of the 
bioluminescence time-course following injections, indicated by arrows in B. C) BL images taken 1 hour prior to and 7 hours 
after immunization. All animals were injected with CFA and OA except where indicated. The total tail tumors in each animal 
during the course of the experiment is enumerated at the bottom of the figure.Retrovirology 2009, 6:116 http://www.retrovirology.com/content/6/1/116
Page 8 of 10
(page number not for citation purposes)
on TAX-LUC mice. Unlike peripheral tumors arising in the
tail or ear, gut tumors include very few if any CD16
expressing cells but an abundance of TCRova + and Tax
expressing cells (Fig. 5E). Taken together, these results
indicate that T cell activation in TCR transgenic TAX-LUC
mice resulted in increased peripheral tumor burden,
decreased survival, and the presentation of a novel form
of visceral lymphoma composed of CD16- TCRova lym-
phocytes similar to tumors that arose in con A treated
TAX-LUC mice.
Discussion
Cells within an inflammatory microenvironment are
capable of promoting malignancy. The cell types involved
in this process, and the mechanisms by which it occurs
have not been fully characterized. While T cells are
recruited to sites of chronic inflammation and are present
in many tumors, they have been shown to have varied
roles in the regulation of cancer. CD8+ cells may play a
role in restricting neoplasms through direct cellular cyto-
toxicity or release of cytokines or chemokines [35].
CD4+CD25+  Treg  cells repress inflammation, but have
been found to be elevated in several different human can-
cers, and suppress immune responses [5]. CD4+ TH17
cells, that secrete IL-17, have been shown to accumulate in
the tumor microenvironment and contribute to the
pathogenesis of cancers [8]. Which of these competing
activities dominates the microenvironment of a chroni-
cally inflamed tumor in vivo? We sought to determine if
activated T- cells repress or promote tumor growth in a
mouse model of inflammation associated cancer. For
these studies, we have used several different forms of gen-
T-cell receptor activation stimulates tumorigenesis in TAX-LUC-DO mice Figure 5
T-cell receptor activation stimulates tumorigenesis in TAX-LUC-DO mice. A) Total number of tumors indicated by 
a single circle for each animal, with closed circles indicating mice immunized with CFA + OA and open circles indicating mice 
immunized with CFA alone. Red bars indicate the average number of tumors for each group. B) Survival curve for TAX-LUC-
DO mice immunized with CFA and OA or CFA alone. C) FACS histograms of TCR expression in tumors that arose on the tail, 
small intestine, or ear of treated triple transgenics. D) Histology of tumors that infiltrated the spleen, lung, and liver as well as 
a comparison of gut and tail tumors. E) TCRova, CD16, and TAX expression in tail and gut tumors from a TAX-LUC-DO 
mouse.Retrovirology 2009, 6:116 http://www.retrovirology.com/content/6/1/116
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eral or specific T- lymphocyte activation and in our exper-
imental model we found that activated T- cells in the
context of inflammation strongly favor a tumor promot-
ing environment. In the animal model we used, Tax trans-
genic tumors are characterized by constitutive NF-kB
activity, expression of IL-1, IL6, TNF-α, and GM-CSF,
severe neutrophilia, and marked osteolytic activity, all of
which are also associated with TH17 activity
[20,21,24,26]. IL-1 and IL-6 produced by tumor cells,
fibroblasts, and APCs are potent in expanding memory
TH17 cells [9]. IL-17 promotes expansion and recruitment
of neutrophils and cooperates with TLR ligands to
enhance inflammatory reactions [10]. While IL-17 is not
expressed by the malignant LGL cells that arise in TAX-
LUC tumors, it is elevated in the serum of tumor-bearing
mice. The role of TH17 cells in promotion of early events
in inflammation-associated tumorigenesis in this model
will be the focus of future studies.
The following model is consistent with information avail-
able to date. Tumorigenesis in TAX-LUC mice begins as a
microscopic intraepithelial lesions associated with acti-
vated neutrophils, detected with luminol, and oncogene
expression, measured by luciferase activity. Among the
inflammatory cells attracted to sites of wounds, neu-
trophils arise first, followed by mast cells and monocytes,
which differentiate into macrophages. It is of interest that
wounding has previously been found to be critical for
tumorigenesis in v-jun transgenic mice [36]. The next step
in tumorigenesis in this model results from the ability of
Tax to directly and indirectly mediate constitutive activa-
tion of both the canonical and non-canonical pathways of
NFkB. This prevents apoptosis and promotes proliferation
of Tax expressing LGL cells that have been recruited to the
wound [13]. The third step in our model is genetic insta-
bility also catalyzed by Tax. Both NFkB activity and
genetic instability are associated with cancers unrelated to
HTLV-1 disease. In our model Tax is simply a mechanism
to accomplish these activities in an accelerated manner in
vivo. The fourth step in TAX-LUC tumor development, the
focus of this work, is the activation of T- cells that have
also been recruited to the wound. Activated T-cells release
cytokines and chemokines, promote induction of angio-
genesis, and regulate the immune response via direct cell
contact and activation of macrophages, dendritic cells,
and neutrophils. The resulting cytokine storm exerts sys-
temic effects with a broad range of biological conse-
quences. Neutrophil infiltration into Tax transgenic
tumors is prominent, and is often accompanied by
peripheral blood neutrophilia [18,26]. Neutrophils may
promote tumor cell proliferation directly. Alternatively,
myeloid-derived suppressor cells have been described
which inhibit anti-tumor immunity [37]. It is noteworthy
that adjuvant-induced inflammation alone was not suffi-
cient to promote tumorigenesis in TAX-LUC or TAX-LUC-
DO mice. The addition of OVA to stimulate the T-cells was
required for the phenotype, indicating a critical role for T-
cells in this step. This model of tumorigenesis for inflam-
mation associated cancers is consistent with the data cur-
rently available and leaves open many avenues of further
inquiry.
Although alternative Tax transgenic models have been
described, only two other models were characterized by
enhanced T- cell proliferation [38-40]. The role of inflam-
mation in those model systems remains to be assessed.
We are currently developing new transgenic lines to pur-
sue these lines of inquiry including TAX-LUC mice in
which i) Tax activity can be experimentally regulated in an
inducible expression system, ii) NFkB signaling is
restricted, or iii) cytokines critical for development or acti-
vation of T- or NK- cells are absent. We propose that the
answers to these questions will have broad implications
to cancers associated with similar mechanisms of origin.
Conclusions
Bioluminescent imaging with HTLV-1 Tax transgenic mice
provided a sensitive marker of inflammation and tumor
formation. Use of this model demonstrated that wound-
ing, T- cell activation, and exposure to chemical agents
exacerbated development of lymphoma.
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